Pas de texte intégral
Article (Périodiques scientifiques)
Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers.
KRÜGER, Rejko; Kuhn, W.; Leenders, K. L. et al.
2001In Neurology, 56 (10), p. 1355-62
Peer reviewed
 

Documents


Texte intégral
Aucun document disponible.

Envoyer vers



Détails



Mots-clés :
Aged; Alanine/genetics; Amino Acid Sequence; Apolipoproteins E/genetics; Brain/pathology/physiopathology; DNA Mutational Analysis; Female; Genotype; Germany; Humans; Male; Middle Aged; Mutation/genetics; Nerve Tissue Proteins/genetics; Neuropsychological Tests; Parkinsonian Disorders/genetics/pathology/psychology; Pedigree; Proline/genetics; Synucleins; Thiolester Hydrolases/genetics; Tomography, Emission-Computed; Ubiquitin Thiolesterase; alpha-Synuclein
Résumé :
[en] BACKGROUND: The authors identified the second known mutation in the alpha-synuclein(SNCA) gene, an alanine-to-proline exchange in amino acid position 30 (A30P), that cosegregates with the disease in one German family with autosomal dominantly inherited parkinsonism (ADP). The authors studied carriers of the A30P mutation to compare the phenotype of this mutation with idiopathic PD (IPD) and to assess nigrostriatal dopaminergic function in symptomatic and preclinical mutation carriers. METHODS: The pedigree of the A30P family spans five generations with five affected individuals. The authors performed detailed neurologic examinations followed by mutation analysis in 11 living individuals. In three mutation carriers, two individuals with definite PD and one person at risk for PD, they used L-[18]F-fluoro-3,4-dihydroxyphenylalanine (F-DOPA), [11]C-raclopride (RAC), and [18]F-fluorodeoxyglucose (FDG) PET to investigate presynaptic dopaminergic function, dopamine D2 receptors, and cerebral energy metabolism. The authors studied the cognitive functions of carriers of the A30P mutation using neuropsychological screening. RESULTS: PET studies revealed striatal presynaptic dopaminergic alterations consistent with sporadic IPD in two affected family members and no evidence for nigrostriatal dopaminergic dysfunction in one presymptomatic mutation carrier. Neuropsychological testing in four mutation carriers provided evidence for cognitive impairment as a frequent and early symptom of the A30P mutation; this is also supported by regional cerebral energy metabolism alterations in the clinically presymptomatic subject. CONCLUSIONS: The phenotype of the A30P mutation in the SNCA gene is similar to that of sporadic IPD, including a high variability of the age at disease onset, ranging from 54 to 76 years. The follow-up of presymptomatic carriers of the A30P mutation may give insight into preclinical disease stages and early manifestations of PD.
Centre de recherche :
- Luxembourg Centre for Systems Biomedicine (LCSB): Clinical & Experimental Neuroscience (Krüger Group)
Disciplines :
Génétique & processus génétiques
Auteur, co-auteur :
KRÜGER, Rejko ;  University of Luxembourg > Faculty of Science, Technology and Communication (FSTC) > Life Science Research Unit
Kuhn, W.
Leenders, K. L.
Sprengelmeyer, R.
Muller, T.
Woitalla, D.
Portman, A. T.
Maguire, R. P.
Veenma, L.
Schroder, U.
Schols, L.
Epplen, J. T.
Riess, O.
Przuntek, H.
Plus d'auteurs (4 en +) Voir moins
Langue du document :
Anglais
Titre :
Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers.
Date de publication/diffusion :
2001
Titre du périodique :
Neurology
ISSN :
0028-3878
Volume/Tome :
56
Fascicule/Saison :
10
Pagination :
1355-62
Peer reviewed :
Peer reviewed
Disponible sur ORBilu :
depuis le 27 juin 2014

Statistiques


Nombre de vues
128 (dont 4 Unilu)
Nombre de téléchargements
0 (dont 0 Unilu)

citations Scopus®
 
147
citations Scopus®
sans auto-citations
136
citations OpenAlex
 
153
citations WoS
 
129

Bibliographie


Publications similaires



Contacter ORBilu